Sign In
Buy BMY
$56.60
+1.88 (+3.44%)
At Close: Jun 04, 2026
Bristol-Myers Squibb: A Tough But Cheap Spot
01:32pm, Tuesday, 21'st Nov 2023
Bristol-Myers Squibb Company is facing challenges due to the loss of exclusivity of its drug Revlimid and the need for new product growth. The company made a transformative deal with the acquisition o
Soothing Stocks: 7 Reliable Picks to Ease Your Market Jitters
08:56pm, Monday, 20'th Nov 2023
Based on the strong print of the major indices since late last month, the idea of deliberately targeting reliable stocks for a volatile market might seem overkill. In the past 30 days, the benchmark S
Three-Stock Lunch: Boeing, Bristol Myers and Krispy Kreme
03:27pm, Monday, 20'th Nov 2023
Sylvia Jablonski, Defiance ETFs CEO and CIO, joins 'Power Lunch' ' to discuss three stocks: Boeing, Bristol Myers and Krispy Kreme Inc.
Midday Movers: Boeing and GM Advance, Bristol-Myers Squibb Declines
01:02pm, Monday, 20'th Nov 2023
U.S. equities began the Thanksgiving holiday-shortened trading week higher at midday after optimism about slowing inflation buoyed markets last week. The Dow, S&P 500, and Nasdaq all gained.
Bristol-Myers Squibb, 2seventy Bio Shares Fall as FDA Delays Decision on Cancer Drug
12:35pm, Monday, 20'th Nov 2023
Shares of Bristol-Myers Squibb (BMY) and partner 2seventy bio (TSVT) slumped after the two companies announced that the Food and Drug Administration (FDA) would not make a decision on expanded use for
Why Bristol Myers Squibb Stock Is Fading Today
11:47am, Monday, 20'th Nov 2023
Bayer announced that it is halting a late-stage trial for asundexian, a high-profile candidate for cardiovascular disease. Bristol Myers Squibb and Johnson & Johnson are co-developing a therapy that b
Why Is Bristol-Myers Squibb (BMY) Stock Down Today?
10:08am, Monday, 20'th Nov 2023
Bristol-Myers Squibb (NYSE: BMY ) stock is falling on Monday after a couple of updates that are weighing on BMY shares today. The first bit of news worth noting are results from a clinical trial of Ba
Bristol Myers Squibb Stock Falls After Drug Approval Delayed
09:42am, Monday, 20'th Nov 2023
Abecma, developed with 2seventy Bio, won't be approved for earlier treatments of a certain kind of blood cancer by a Dec. 16 deadline.
Bristol-Meyers Squibb shares fall as FDA delays blood cancer therapy decision
09:31am, Monday, 20'th Nov 2023
Bristol-Myers Squibb Co (NYSE:BMY) shares fell almost 5% after the company announced that a Food and Drug Administration (FDA) decision on the use of its blood cancer therapy Abecma, developed with pa
Bristol Myers Squibb, 2seventy bio shares fall as FDA delays action on cancer treatment
08:35am, Monday, 20'th Nov 2023
Shares of Bristol Myers Squibb Co. BMY and 2seventy bio Inc. TSVT fell premarket on Monday after the companies said the U.S. Food and Drug Administration would miss its target date for potential appro
2 overlooked stocks that crushed earnings but traded lower
06:22am, Monday, 20'th Nov 2023
As the third quarter 2023 earnings season ends, it's worth looking back to see which stocks may have been overlooked or mispriced on their results. Regardless of sector or industry, every earnings sea
Bristol Myers Squibb: Bright Future Ahead
04:46am, Friday, 17'th Nov 2023
Bristol Myers Squibb is facing short-term pressure on financial results due to generic growth impacting its flagship drug Revlimid. BMY is actively investing in new drugs and companies to strengthen i
Bristol Myers (BMY) Receives FDA Approval for NSCLC Drug
12:47pm, Thursday, 16'th Nov 2023
Bristol Myers' (BMY) repotrectinib, a tyrosine kinase inhibitor (???TKI???) targeting ROS1 oncogenic fusions, gets FDA?
US FDA approves Bristol-Myers' lung cancer drug
05:03pm, Wednesday, 15'th Nov 2023
The U.S. Food and Drug Administration (FDA) on Wednesday approved Bristol-Myers' drug to treat patients with a type of lung cancer.
Bristol Myers Squibb Proved in Q3 Why Its Diverse Portfolio Makes It a Solid Investment
10:01am, Tuesday, 14'th Nov 2023
Sales of Revlimid fell 41% last quarter, and yet Bristol Myers' top line was down just 2%. The company has been bolstering its portfolio of new products over the years, and that appears to be paying o
